OR WAIT null SECS
November 07, 2023
Matthew Lauber, senior director—Cell and Gene Therapy, Consumables & Lab Automation, at Waters Corporation discusses the analytical and downstream purification challenges of oligonucleotides.
October 11, 2023
Under this agreement, Acuitas Therapeutics’ LNP technology platform will be transferred to BIOVECTRA for use in manufacturing mRNA-based therapies.
September 28, 2023
With the two new GMP-grade mRNA manufacturing sites in Germany, MilliporeSigma can now offer fully integrated mRNA services.
July 14, 2023
German manufacturer metabion is conducting a multi-million euro expansion of its oligonucleotide manufacturing capacity in Munich East.
July 07, 2023
Camena Bioscience has completed $10 million in Series A financing on the back of growing demand for DNA synthesis.
May 16, 2023
Synthego has opened its new GMP-compliant RNA manufacturing facility in Redwood City, Calif., for CRISPR-enabled genomics therapeutics.
May 15, 2023
To prepare for emerging mRNA technologies, it is necessary to adapt fill/finish and cold chain capabilities.
May 10, 2023
The market potential of nucleic acid-based therapies have been pushed into the spotlight following the success of the COVID-19 vaccines.
April 02, 2023
The COVID-19 vaccines opened the door to powerful market potential for other nucleic acid-based therapies.
March 01, 2023
Considerable efforts have been made over the years to resolve the key issues of stability and delivery of RNA-based therapeutics.